NASDAQ · AMGN
Healthcare · Drug Manufacturers - General
$460.73
Up+$5.28 (+1.15%)
Updated Oct 31, 2026, 1:01 AM
SID Score
7.3/10
Composite research score
Smart Money
51/100
Neutral
Price performance · AMGN
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
AMGN closed at $460.73 after 20 trading sessions, up 14.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $465.57 | $468.27 | $457.355 | $460.73 | 2.98M |
| Oct 28, 2026 | $441.03 | $454.66 | $439.57 | $451.83 | 2.91M |
| Oct 27, 2026 | $441.80 | $448.545 | $439.2801 | $447.95 | 1.73M |
| Oct 26, 2026 | $444.89 | $449.80 | $439.50 | $444.63 | 2.05M |
| Oct 23, 2026 | $444.40 | $444.59 | $439.07 | $439.26 | 2.07M |
| Oct 22, 2026 | $441.55 | $450.98 | $437.1944 | $447.28 | 3.11M |
| Oct 21, 2026 | $440.21 | $441.03 | $434.53 | $438.34 | 2.61M |
| Oct 20, 2026 | $425.58 | $439.05 | $425.11 | $438.94 | 2.22M |
| Oct 19, 2026 | $430.355 | $434.51 | $424.74 | $424.94 | 2.68M |
| Oct 16, 2026 | $437.89 | $438.82 | $431.39 | $432.49 | 2.57M |
| Oct 15, 2026 | $435.83 | $441.7599 | $433.42 | $434.03 | 4.63M |
| Oct 14, 2026 | $417.83 | $428.05 | $415.1951 | $426.11 | 3.09M |
| Oct 13, 2026 | $420.34 | $420.35 | $411.04 | $412.84 | 2.32M |
| Oct 12, 2026 | $416.12 | $417.76 | $413.44 | $417.57 | 1.72M |
| Oct 9, 2026 | $405.00 | $417.78 | $404.05 | $414.87 | 2.55M |
| Oct 8, 2026 | $409.97 | $411.84 | $400.06 | $407.44 | 2.38M |
| Oct 7, 2026 | $403.06 | $415.79 | $401.85 | $413.08 | 2.24M |
| Oct 6, 2026 | $403.30 | $405.00 | $396.01 | $402.60 | 2.04M |
| Oct 5, 2026 | $399.03 | $403.69 | $397.03 | $402.98 | 3.1M |
| Oct 2, 2026 | $410.16 | $410.16 | $401.96 | $403.04 | 3.51M |
The latest Smart Investors Daily articles mentioning AMGN.
Company
Market Activity
Research & News
AMGN research
Company profile and research snapshot.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 23, 2026 | Oppenheimer | Outperform | — |
| Oct 21, 2026 | Barclays | Equal-Weight | — |
| Oct 13, 2026 | Guggenheim | Neutral | — |
| Oct 12, 2026 | Wells Fargo | Equal-Weight | — |
| Oct 12, 2026 | BMO Capital | Market Perform | — |
Generated Oct 30, 2026, 9:03 PM
Amgen shares gained 1.15% today as the biotech giant prepares to report third-quarter earnings, though analyst sentiment remains cautiously pessimistic heading into the results. The stock's modest gains reflect a market weighing strong drug sales potential against rising expense headwinds and competitive pressures in the GLP-1 weight loss drug space.
Bottom line: Amgen's modest 1.15% gain today reflects investor optimism tempered by significant earnings execution risk, with analysts expressing clear doubts about whether the company can justify valuations amid rising expense pressures. Investors should focus on Q3 results for clues on revenue quality, cost management, and the pipeline's competitive positioning—particularly in high-growth areas like rare diseases and GLP-1 therapeutics.
Yahoo · Oct 30, 2026
The S&P 500 Index ($SPX ) (SPY ) is down -1.26%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.52%. December E-mini S&P futures (ESZ26 ) are down -1.33%, and December E-mini Nasdaq futures (NQZ26...
Yahoo · Oct 30, 2026
AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.
Yahoo · Oct 30, 2026
Collecting four figures a month from dividends without ever selling a share sounds straightforward until you price out what it actually costs and see which companies are holding the whole structure together.
SeekingAlpha · Oct 30, 2026
Amgen appears safe, but the current valuation above $450/share may prove expensive by Q3 2026. Click here to read an analysis of AMGN stock now.
Interpretive context generated from the platform’s current data sources.
Amgen Inc. shares closed at $460.73, reflecting a single-session decline of 2.50% per SID market data. Despite the daily pullback, the stock has demonstrated strong momentum across multiple timeframes, gaining 6.65% over the trailing one-month period, 16.56% over three months, and 40.88% over the past year. The stock trades well above both its 50-day moving average of $418.95 and its 200-day moving average of $376.32, indicating a sustained bullish trend according to Massive/Polygon technical data. However, the 14-day relative strength index stands at 74.9, placing shares in overbought territory above the conventional 70 threshold. Amgen carries a beta of 0.472, reflecting significantly lower volatility relative to the broader market. Average daily trading volume registers at approximately 2.89 million shares, supporting adequate liquidity for the company's $209.2 billion market capitalization.
Amgen currently trades at a price-to-earnings ratio of 27.13, which sits above the historical average for large-cap biopharmaceutical companies, per SID market data. The PEG ratio stands at 2.72, suggesting the stock's valuation is elevated relative to its expected earnings growth rate. The price-to-book ratio registers at 24.16, a level that reflects the company's significant intangible asset base, including intellectual property and goodwill from acquisitions, according to SEC filings. Amgen offers a dividend yield of 2.49%, providing meaningful income relative to the broader healthcare sector. Within the healthcare sector, Amgen's premium valuation metrics reflect investor confidence in its pipeline and revenue durability. The combination of a high P/E ratio and PEG ratio above 2.0 indicates that shares are currently priced for robust future performance, with the dividend yield partially offsetting the valuation premium for income-oriented investors.
Amgen's composite smart money score stands at 51 out of 100, generating a neutral signal per SID market data. Institutional ownership conviction scores a perfect 25 out of 25, indicating maximum confidence among large fund managers based on 13F institutional filings. In contrast, insider sentiment scores 8.6 out of 25, with 15 insider transactions recorded over the past 90 days according to SEC Form 4 filings. Of those trades, nine were purchases and six were sales, producing a modestly positive buy-to-sell ratio. Dark pool activity registers at 8.5 out of 25, suggesting below-average institutional block trading interest at current price levels. Congressional trading activity scores 8.8 out of 25, reflecting limited legislative member involvement. The divergence between the maximum institutional score and the lower insider and dark pool readings creates a mixed overall picture. The perfect institutional score underscores sustained conviction from major asset managers, while the below-median insider and dark pool metrics temper the aggregate signal.
Amgen has delivered three consecutive quarters of earnings beats according to company earnings reports. In the most recent reported quarter, the company posted earnings per share of $6.29 against an analyst estimate of $5.60, representing a positive surprise of $0.69, or 12.3%. The prior quarter showed EPS of $5.15 versus the $4.76 consensus estimate, a $0.39 beat. The quarter before that delivered $5.29 against a $4.75 estimate, exceeding expectations by $0.54. This consistent pattern of outperformance demonstrates the company's ability to exceed Wall Street projections across varying seasonal periods. Looking ahead, analyst estimates project fourth-quarter earnings of $5.78 per share, with the report scheduled for November 3. The upward trajectory from $5.15 to $6.29 in sequential reported quarters highlights accelerating profitability. Investors will monitor whether the company can sustain its beat streak in the upcoming report.
Recent Wall Street analyst activity on Amgen reflects a predominantly hold-oriented consensus, per SID consensus data. In October 2026, five firms issued or reiterated ratings on the stock. Oppenheimer maintained its Outperform rating on October 23, representing the sole bullish stance among recent coverage updates according to Wall Street analyst reports. Barclays reiterated its Equal-Weight rating on October 21, while Guggenheim maintained a Neutral stance on October 13. Wells Fargo and BMO Capital both reiterated Equal-Weight and Market Perform ratings, respectively, on October 12. Notably, none of the five analysts changed their ratings from prior assessments, indicating stable sentiment rather than shifting conviction. The distribution of four neutral-equivalent ratings against one outperform suggests that the majority of covering analysts view AMGN as fairly valued near current levels. The absence of any downgrades or sell ratings provides a supportive floor, while the limited upgrade activity reflects caution following the stock's 40.88% one-year advance.
The latest Smart Investors Daily articles mentioning AMGN.
